tiprankstipranks
Blurbs

Alzamend Neuro (ALZN) Gets a Buy from Univest Securities

In a report released on September 30, James Jang from Univest Securities maintained a Buy rating on Alzamend Neuro (ALZNResearch Report), with a price target of $15.00. The company’s shares closed last Friday at $1.19.

According to TipRanks, Jang is an analyst with an average return of -9.2% and a 34.69% success rate.

Currently, the analyst consensus on Alzamend Neuro is a Moderate Buy with an average price target of $15.00.

See Insiders’ Hot Stocks on TipRanks >>

ALZN market cap is currently $113.6M and has a P/E ratio of -8.46.

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALZN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s.

Read More on ALZN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles